PHIA Koninklijke Philips N.V.

Philips publishes its Annual Report 2023

Philips publishes its Annual Report 2023

February 20, 2024

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2023.

Philips’ Annual Report 2023 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 7, 2024. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course.

Philips filed the Annual Report 2023 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to file the report on Form 20-F with the U.S. Securities and Exchange Commission later today ().

 

The Annual Report 2023 (in ESEF and on Form 20-F) is available to shareholders and other interested parties at . A printed copy can be obtained free of charge upon written request to the following email address: .

For further information, please contact:

Ben Zwirs

Philips External Relations

Tel.:

E-mail:

Dorin Danu

Philips Investor Relations

Tel.:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,700 employees with sales and services in more than 100 countries. News about Philips can be found at .

Forward-looking statements

This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.



EN
20/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Nicklaus Children’s Health System, Philips to provide innovative patie...

Nicklaus Children’s Health System, Philips to provide innovative patient and staff experience, helping to enhance outcomes for the smallest of patients April 30, 2024 Philips AI-enabled diagnostic and experiential technologies help put patients at ease while empowering staff with faster, high-quality scans and increased diagnostic confidence Amsterdam, the Netherlands, and Miami, US – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Nicklaus Children’s Health System, a nationally recognized leader in pediatric care, today announced a 10-year long-term strategic collabora...

Marc Hesselink ... (+3)
  • Marc Hesselink
  • CFA
  • Thymen Rundberg

Philips/Very welcome clearing event/HOLD

At its 1Q24 update Philips surprised the market with a personal injury settlement which has been made much sooner than expected and, at €1bn, is a much lower cost than the €3bn we had in our model. We believe this is a major positive for the investment case. We increase our target price from €19 to €25. We stick to our HOLD rating as: (1) current trading conditions are mixed; and (2) valuation is now fair compared to peers.

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Alfen: Production resumed in mid-April, cost hit €5m. Exor: Read-across from Philips personal injury settlement. Philips: 1Q24 results – settlement reached. Recticel: 1Q24 in line with expectations. Sofina: Exit Petit Forestier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch